Epic Sciences, Inc., a San Diego, CA-based biotech company that develops cancer diagnostics, has completed a $13m Series B equity financing.
Backers include new investors Domain Associates, Roche Venture Fund, and Pfizer Venture Investments, as well as undisclosed individual investors.
In conjunction with the financing, Kim Kamdar, Ph.D. will join Epic’s board of directors.
The company intends to use the capital to expand research and development operations and capabilities to commercialize its CTC platform.
Led by Dr. David Nelson, president and CEO, Epic Sciences, Epic is developing diagnostic tests that molecularly characterize circulating tumor cells (CTCs) in the blood to provide a way to detect cancer and to monitor and personalize cancer treatments.
The basis of the company’s CTC platform has been exclusively licensed from Dr. Peter Kuhn’s laboratory at The Scripps Research Institute. Epic is currently working with seven pharmaceutical partners to create companion diagnostic products for oncology drug candidates. The partnerships include a number of Phase I and II clinical trials ultimately involving more than 1,500 patients.